Helix BioPharma announces management change

Helix BioPharma, an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced Steve Demas, its Chief Operating Officer, has resigned due to personal reasons.

“I want to thank Steve on behalf of Helix for his significant contribution to the Company,” said Heman Chao, CEO.

“I wish him the best in his future endeavours.”